Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) have earned a consensus recommendation of “Hold” from the ten analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $24.33.

Several equities research analysts recently issued reports on AMRX shares. Morgan Stanley started coverage on Amneal Pharmaceuticals in a report on Monday, July 23rd. They issued an “overweight” rating and a $22.00 price objective on the stock. Canaccord Genuity reiterated a “hold” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a report on Tuesday, September 4th. ValuEngine cut Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 27th. B. Riley started coverage on Amneal Pharmaceuticals in a report on Friday, June 22nd. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $35.00 price objective on shares of Amneal Pharmaceuticals in a report on Thursday, August 9th.

AMRX stock traded up $0.16 during trading on Friday, hitting $18.81. The stock had a trading volume of 1,122,246 shares, compared to its average volume of 1,185,310. The company has a current ratio of 2.01, a quick ratio of 1.25 and a debt-to-equity ratio of 2.85. Amneal Pharmaceuticals has a twelve month low of $13.47 and a twelve month high of $24.48. The stock has a market cap of $6.62 billion, a price-to-earnings ratio of 29.86, a PEG ratio of 0.98 and a beta of 1.41.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Thursday, August 9th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.01. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The company had revenue of $462.33 million for the quarter, compared to analysts’ expectations of $460.82 million. Amneal Pharmaceuticals’s revenue was down 2.5% on a year-over-year basis. As a group, equities analysts forecast that Amneal Pharmaceuticals will post 0.96 EPS for the current fiscal year.

In other news, CFO Bryan M. Reasons sold 11,698 shares of the business’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total transaction of $276,657.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nikita Shah sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total value of $1,173,000.00. The disclosure for this sale can be found here. Insiders own 3.20% of the company’s stock.

Several institutional investors have recently modified their holdings of AMRX. Xact Kapitalforvaltning AB acquired a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $203,000. Bank of Montreal Can acquired a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $541,000. Scout Investments Inc. acquired a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $1,752,000. Fox Run Management L.L.C. purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at approximately $228,000. Finally, Boston Advisors LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at approximately $613,000. Institutional investors and hedge funds own 32.41% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Featured Article: New Google Finance Tool and Screening Stocks

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.